AstraZeneca (AZN +0.3%) says results from its PLATO study of a greater reduction in thrombotic...

|About: AstraZeneca Group plc (AZN)|By:, SA News Editor

AstraZeneca (AZN +0.3%) says results from its PLATO study of a greater reduction in thrombotic cardiovascular events with Brilinta tablets plus aspirin compared to clopidogrel plus aspirin were consistent regardless of age. The data is now published in the September issue of Circulation: Cardiovascular Quality and Outcomes, and were presented at the American College of Cardiology.